We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

53 hedge funds and large institutions have $48.9M invested in VanEck Pharmaceutical ETF in 2014 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

23% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 13

20% more capital invested

Capital invested by funds: $40.9M → $48.9M (+$8M)

10% more funds holding

Funds holding: 48 → 53 (+5)

0.28% more ownership

Funds ownership: 15.27% → 15.55% (+0.28%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
53
Holders Change
+5
Holders Change %
+10.42%
% of All Funds
1.53%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
8
Increased
16
Reduced
13
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RJA
Raymond James & Associates
Florida
+$4.54M
2
HighTower Advisors
HighTower Advisors
Illinois
+$2.01M
3
B
Baird
Wisconsin
+$1.31M
4
BCM
Barometer Capital Management
Ontario, Canada
+$599K
5
U
UBS
Switzerland
+$574K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$5.68M
2
Goldman Sachs
Goldman Sachs
New York
-$657K
3
MIM
Macroview Investment Management
Maryland
-$388K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$201K
5
CCT
Country Club Trust
Missouri
-$201K
Name Holding Trade Value Shares
Change 		Change in
Stake
FPCM
26
Financial Partners Capital Management
New York
$358K -$2.83K -50 -0.8%
VKH
27
Virtu KCG Holdings
New York
$352K +$10.1K +178 +3%
CNB
28
City National Bank
California
$344K – – –
JWM
29
Jacobus Wealth Management
Wisconsin
$325K – – –
Bank of Montreal
30
Bank of Montreal
Ontario, Canada
$318K -$201K -3,555 -39%
KFC
31
Klingenstein Fields & Co
New York
$280K – – –
FMW
32
Farr Miller & Washington
District of Columbia
$233K +$226K +4,000 New
OPCM
33
Osborne Partners Capital Management
California
$222K -$22.6K -400 -10%
MA
34
MUFG Americas
New York
$168K -$11.3K -200 -6%
LTFS
35
Ladenburg Thalmann Financial Services
Florida
$142K +$95.6K +1,691 +229%
TCM
36
Tradewinds Capital Management
Washington
$140K – – –
PNC Financial Services Group
37
PNC Financial Services Group
Pennsylvania
$121K – – –
Deutsche Bank
38
Deutsche Bank
Germany
$93K +$46.4K +820 +105%
DADC
39
D.A. Davidson & Co
Montana
$77K – – –
MFS
40
MSI Financial Services
Massachusetts
$74K -$4.3K -76 -6%
Wells Fargo
41
Wells Fargo
California
$58K -$192K -3,400 -77%
GT
42
Glenmede Trust
Pennsylvania
$58K – – –
NES
43
New England Securities
New York
$53K +$21.8K +385 +74%
HCM
44
Highlander Capital Management
New Jersey
$29.2K – – –
EAMA
45
EFG Asset Management (Americas)
Florida
$22K – – –
Citigroup
46
Citigroup
New York
$20K -$4.64K -82 -19%
FAM
47
Formidable Asset Management
Ohio
$12K – – –
Ameriprise
48
Ameriprise
Minnesota
$6K – – –
WA
49
WFG Advisors
Texas
$6K – – –
HR
50
Howe & Rusling
New York
$6K +$1.41K +25 +33%
1
2
3

PPH Hedge Fund Activity: Q1 2014 in Review

53 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2014, worth a combined $48.9M — up 20% from $40.9M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new PPH positions and 3 closed out — a net gain of 5 holders — while 16 added to existing stakes and 13 trimmed.

The largest buyer was Raymond James & Associates, opening a new position worth an estimated $4.54M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $5.68M sold.

  • 53 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2014, up from 48 in Q4 2013.
  • Funds reported $48.9M of VanEck Pharmaceutical ETF stock for Q1 2014, up 20% quarter-over-quarter.
  • 8 funds opened new VanEck Pharmaceutical ETF positions in Q1 2014 and 3 closed out, a net change of +5 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q1 2014 was Raymond James & Associates, an estimated $4.54M added.
  • The largest VanEck Pharmaceutical ETF seller in Q1 2014 was JP Morgan Chase, an estimated $5.68M sold.

Based on aggregated 13F filings for Q1 2014.